Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in Nat Med Retrieve available abstracts of 46 articles: HTML format

Single Articles

February 2021
1. CASCONE T, William WN Jr, Weissferdt A, Leung CH, et al
   Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
   Nat Med. 2021 Feb 18. pii: 10.1038/s41591-020-01224.
   PubMed     Abstract available
   
   
   
2. BACHELOT T, Filleron T, Bieche I, Arnedos M, et al
   Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
   Nat Med. 2021;27:250-255.
   PubMed     Abstract available
   
   
   January 2021
3. STOWER H
   A map of lung cell types.
   Nat Med. 2021;27:21.
   PubMed    
   
   
   
4. YU J, Green MD, Li S, Sun Y, et al
   Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
   Nat Med. 2021;27:152-164.
   PubMed     Abstract available
   
   
   August 2020
5. BRASTIANOS PK, Lee EQ, Cohen JV, Tolaney SM, et al
   Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
   Nat Med. 2020;26:1280-1284.
   PubMed     Abstract available
   
   
   July 2020
6. ABDULJABBAR K, Raza SEA, Rosenthal R, Jamal-Hanjani M, et al
   Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
   Nat Med. 2020;26:1054-1062.
   PubMed     Abstract available
   
   
   June 2020
7. LU Y, Xue J, Deng T, Zhou X, et al
   Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
   Nat Med. 2020 Jun 18. pii: 10.1038/s41591-020-0973.
   PubMed     Abstract available
   
   
   
8. BISWAS D, Birkbak NJ, Rosenthal R, Hiley CT, et al
   Publisher Correction: A clonal expression biomarker associates with lung cancer mortality.
   Nat Med. 2020 Jun 3. pii: 10.1038/s41591-020-0899.
   PubMed     Abstract available
   
   
   
9. JOSHI K, de Massy MR, Ismail M, Reading JL, et al
   Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
   Nat Med. 2020 Jun 3. pii: 10.1038/s41591-020-0866.
   PubMed     Abstract available
   
   
   
10. BOCKORNY B, Semenisty V, Macarulla T, Borazanci E, et al
    BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
    Nat Med. 2020;26:878-885.
    PubMed     Abstract available
    
    
    April 2020
11. LU Y, Xue J, Deng T, Zhou X, et al
    Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
    Nat Med. 2020 Apr 27. pii: 10.1038/s41591-020-0840.
    PubMed     Abstract available
    
    
    February 2020
12. LAUGHNEY AM, Hu J, Campbell NR, Bakhoum SF, et al
    Regenerative lineages and immune-mediated pruning in lung cancer metastasis.
    Nat Med. 2020;26:259-269.
    PubMed     Abstract available
    
    
    
13. HATA AN, Shaw AT
    Resistance looms for KRAS(G12C) inhibitors.
    Nat Med. 2020;26:169-170.
    PubMed    
    
    
    January 2020
14. DRILON A, Clark JW, Weiss J, Ou SI, et al
    Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
    Nat Med. 2020;26:47-51.
    PubMed     Abstract available
    
    
    November 2019
15. CHOWELL D, Krishna C, Pierini F, Makarov V, et al
    Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.
    Nat Med. 2019;25:1715-1720.
    PubMed     Abstract available
    
    
    
16. KIM JW, Marquez CP, Kostyrko K, Koehne AL, et al
    Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
    Nat Med. 2019;25:1783-1795.
    PubMed     Abstract available
    
    
    October 2019
17. BISWAS D, Birkbak NJ, Rosenthal R, Hiley CT, et al
    A clonal expression biomarker associates with lung cancer mortality.
    Nat Med. 2019 Oct 7. pii: 10.1038/s41591-019-0595.
    PubMed     Abstract available
    
    
    
18. JOSHI K, Robert de Massy M, Ismail M, Reading JL, et al
    Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
    Nat Med. 2019 Oct 4. pii: 10.1038/s41591-019-0592.
    PubMed     Abstract available
    
    
    
19. GANESH K, Wu C, O'Rourke KP, Szeglin BC, et al
    A rectal cancer organoid platform to study individual responses to chemoradiation.
    Nat Med. 2019;25:1607-1614.
    PubMed     Abstract available
    
    
    
20. CHEMI F, Rothwell DG, McGranahan N, Gulati S, et al
    Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.
    Nat Med. 2019;25:1534-1539.
    PubMed     Abstract available
    
    
    
21. COURTIOL P, Maussion C, Moarii M, Pronier E, et al
    Deep learning-based classification of mesothelioma improves prediction of patient outcome.
    Nat Med. 2019;25:1519-1525.
    PubMed     Abstract available
    
    
    September 2019
22. YANG H, Xia L, Chen J, Zhang S, et al
    Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity.
    Nat Med. 2019;25:1428-1441.
    PubMed     Abstract available
    
    
    June 2019
23. ARDILA D, Kiraly AP, Bharadwaj S, Choi B, et al
    Author Correction: End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography.
    Nat Med. 2019 Jun 28. pii: 10.1038/s41591-019-0536.
    PubMed     Abstract available
    
    
    May 2019
24. ARDILA D, Kiraly AP, Bharadwaj S, Choi B, et al
    End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography.
    Nat Med. 2019 May 20. pii: 10.1038/s41591-019-0447.
    PubMed     Abstract available
    
    
    
25. STOWER H
    Evading the immune system.
    Nat Med. 2019;25:710.
    PubMed    
    
    
    
26. WANG Z, Yip LY, Lee JHJ, Wu Z, et al
    Methionine is a metabolic dependency of tumor-initiating cells.
    Nat Med. 2019;25:825-837.
    PubMed     Abstract available
    
    
    
27. RODON J, Soria JC, Berger R, Miller WH, et al
    Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
    Nat Med. 2019;25:751-758.
    PubMed     Abstract available
    
    
    March 2019
28. ABBOTT B
    Spreading the search.
    Nat Med. 2019;25:352-355.
    PubMed    
    
    
    January 2019
29. TEIXEIRA VH, Pipinikas CP, Pennycuick A, Lee-Six H, et al
    Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.
    Nat Med. 2019 Jan 21. pii: 10.1038/s41591-018-0323.
    PubMed     Abstract available
    
    
    November 2018
30. SHAH KN, Bhatt R, Rotow J, Rohrberg J, et al
    Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
    Nat Med. 2018 Nov 26. pii: 10.1038/s41591-018-0264.
    PubMed     Abstract available
    
    
    
31. FORMENTI SC, Rudqvist NP, Golden E, Cooper B, et al
    Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
    Nat Med. 2018 Nov 5. pii: 10.1038/s41591-018-0232.
    PubMed     Abstract available
    
    
    September 2018
32. COUDRAY N, Ocampo PS, Sakellaropoulos T, Narula N, et al
    Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning.
    Nat Med. 2018 Sep 17. pii: 10.1038/s41591-018-0177.
    PubMed     Abstract available
    
    
    August 2018
33. DERIBE YL, Sun Y, Terranova C, Khan F, et al
    Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
    Nat Med. 2018 Aug 13. pii: 10.1038/s41591-018-0173.
    PubMed     Abstract available
    
    
    
34. HOYLES L, Fernandez-Real JM, Federici M, Serino M, et al
    Publisher Correction: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.
    Nat Med. 2018 Aug 9. pii: 10.1038/s41591-018-0169.
    PubMed     Abstract available
    
    
    
35. GUO X, Zhang Y, Zheng L, Zheng C, et al
    Publisher Correction: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.
    Nat Med. 2018 Aug 9. pii: 10.1038/s41591-018-0167.
    PubMed     Abstract available
    
    
    
36. GANDARA DR, Paul SM, Kowanetz M, Schleifman E, et al
    Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
    Nat Med. 2018 Aug 6. pii: 10.1038/s41591-018-0134.
    PubMed     Abstract available
    
    
    June 2018
37. GUO X, Zhang Y, Zheng L, Zheng C, et al
    Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.
    Nat Med. 2018 Jun 25. pii: 10.1038/s41591-018-0045.
    PubMed     Abstract available
    
    
    
38. THOMMEN DS, Koelzer VH, Herzig P, Roller A, et al
    A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
    Nat Med. 2018 Jun 11. pii: 10.1038/s41591-018-0057.
    PubMed     Abstract available
    
    
    
39. LISSANU DERIBE Y, Sun Y, Terranova C, Khan F, et al
    Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
    Nat Med. 2018 Jun 8. pii: 10.1038/s41591-018-0019.
    PubMed     Abstract available
    
    
    May 2018
40. MAINARDI S, Mulero-Sanchez A, Prahallad A, Germano G, et al
    SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Nat Med. 2018 May 28. pii: 10.1038/s41591-018-0023.
    PubMed     Abstract available
    
    
    April 2018
41. ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al
    Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Nat Med. 2018 Apr 23. pii: 10.1038/s41591-018-0007.
    PubMed     Abstract available
    
    
    March 2018
42. DARDAEI L, Wang HQ, Singh M, Fordjour P, et al
    SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
    Nat Med. 2018 Mar 5. pii: nm.4497. doi: 10.1038/nm.4497.
    PubMed     Abstract available
    
    
    October 2017
43. ROMERO R, Sayin VI, Davidson SM, Bauer MR, et al
    Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
    Nat Med. 2017 Oct 2. doi: 10.1038/nm.4407.
    PubMed     Abstract available
    
    
    August 2017
44. XUE Y, Martelotto L, Baslan T, Vides A, et al
    An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
    Nat Med. 2017;23:929-937.
    PubMed     Abstract available
    
    
    July 2017
45. MAYORCA-GUILIANI AE, Madsen CD, Cox TR, Horton ER, et al
    ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix.
    Nat Med. 2017;23:890-898.
    PubMed     Abstract available
    
    
    June 2017
46. RICKMAN DS, Beltran H, Demichelis F, Rubin MA, et al
    Biology and evolution of poorly differentiated neuroendocrine tumors.
    Nat Med. 2017;23:1-10.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: